Neautus launches Hong Kong IPO at up to HK$3.3 billion valuation
Sichuan Neautus Traditional Chinese Medicine Co. Ltd. (2206.HK) launched its Hong Kong IPO on Oct. 30, targeting a valuation of up to HK$3.3 billion ($423 million), as it seeks to…
Biokin’s world-first bispecific ADC hits milestones, speeding commercialization
Iza-bren was approved for recurrent or metastatic esophageal squamous cell carcinoma, after receiving earlier approval to treat nasopharyngeal carcinoma Key Takeaways: New approvals for Biokin’s Iza-bren highlight the rise of…
Tong Ren Tang Healthcare makes trading debut, backed by 39% annual patient growth
The company will use a majority of the $68 million it raised from its Hong Kong listing to expand its network of traditional Chinese medicine hospitals and clinics Key Takeaways:…
Shaanxi Micot shares nearly double in Hong Kong trading debut
Shares of drugmaker Shaanxi Micot Pharmaceutical Technology Co. Ltd. (2335.HK) jumped in their Hong Kong trading debut on Wednesday, after the company raised HK$989 million ($126 million) by selling about…
Asia’s probiotic leader looks for nourishment from Hong Kong IPO
Wecare Probiotics ranked third globally and first in Asia by probiotic raw powder production volume in 2025, even as large amounts of its capacity lay idle last year Key Takeaways:…
Looking for overseas growth, Aier Eye seeks Hong Kong listing
The leading Chinese chain of private eye hospitals is aiming to boost its brand visibility and widen its funding options, but will it be able to justify a juicy premium?…
JD Health’s AI push sets up a battle of the digital doctors
The Chinese healthcare platform enjoys a thriving online pharmacy business and is investing heavily in AI tools, but powerful rivals are entering the same arena Key Takeaways: Competitors such as…
Recent Articles
RELATED ARTICLES
-
Traditional Chinese medicine leader Yuyantang finds tonic in aging population
- Tong Ren Tang Healthcare makes trading debut, backed by 39% annual patient growth
-
JBM Healthcare gets bitter pill from investors on anemic performance
2161.HK
- Gushengtang steps up TCM buying spree, doubling down in Beijing
- Moonshot aims for meteoric valuation with a $3 billion Hong Kong IPO plan
-
Apple supplier Luxshare launches $3 billion Hong Kong IPO
002475.SHE
-
Dongshan Precision launches $1.3 billion Hong Kong IPO
2384.HK002384.SHE
